DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 022041/S-019
NDA 022041/S-020

SUPPLEMENT APPROVAL

SERB S.A.
c/o Cindy Marshall Consulting
PO Box 9222
Chapel Hill, NC 27515

Attention: Cindy N. Marshall, RAC
US Agent for SERB

Dear Ms. Marshall:

Please refer to your Supplemental New Drug Applications (sNDAs) for Supplement 019 dated April 28, 2017, and received May 1, 2017, and Supplement 020 dated and received December 8, 2017, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Cyanokit (hydroxocobalamin for injection) for intravenous infusion.

S-019, a CBE-30 supplemental new drug application provides for following changes: revisions to the **WARNINGS AND PRECAUTIONS** section of the Package Insert to include new safety information, including renal-related events, that was identified in preparation of the periodic adverse drug experience report.

S-020, a Prior Approval supplemental new drug application proposes the following changes: revisions to the **USE IN SPECIFIC POPULATIONS** section of the package insert in accordance with the Pregnancy and Lactation Labeling Rule (PLLR) and revisions to the **CLINICAL PHARMACOLOGY** section of the package insert to comply with the Guidance for Industry Clinical Pharmacology Section of Labeling for Human Prescription Drug and Biological Products. In addition, the patient package insert was revised to enhance patient comprehension.

APPROVAL & LABELING

We have completed our review of these supplemental applications, as amended and are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the prescribing information, text for the patient package insert), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Eva Yuan, PharmD, Regulatory Project Manager, at 240-402-2476.

Sincerely,

{See appended electronic signature page}

Rigoberto Roca, MD
Deputy Director
Division of Anesthesia, Analgesia,
and Addiction Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

ENCLOSURE:
Content of Labeling

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

RIGOBERTO A ROCA
12/31/2018 08:46:31 AM